Literature DB >> 11095817

US Food and Drug Administration Approval of Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis: A Model for Orphan Drug Development.

.   

Abstract

Entities:  

Year:  1999        PMID： 11095817     DOI： 10.1007/s11908-999-0052-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  6 in total

1.  U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.

Authors:  J D Berman
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

Review 2.  U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.

Authors:  A Meyerhoff
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

3.  Visceral leishmaniasis treated with liposomal amphotericin B.

Authors:  S Catania; C Aiassa; S Tzahtzoglou; N Catania; L Tucciarone; A Antimi; G Ragni; A Clerico
Journal:  Pediatr Infect Dis J       Date:  1999-01       Impact factor: 2.129

4.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Authors:  J D Berman; R Badaro; C P Thakur; K M Wasunna; K Behbehani; R Davidson; F Kuzoe; L Pang; K Weerasuriya; A D Bryceson
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

5.  Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis.

Authors:  G W Wortmann; S L Fraser; N E Aronson; C Davis; R S Miller; J D Jackson; C N Oster
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

6.  Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

Authors:  S Sundar; A K Goyal; D K More; M K Singh; H W Murray
Journal:  Ann Trop Med Parasitol       Date:  1998-10
  6 in total
  2 in total

1.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 2.  Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization.

Authors:  Ning Wang; Minnan Chen; Ting Wang
Journal:  J Control Release       Date:  2019-05-03       Impact factor: 9.776
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.